title: Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
abstract: 24-nor-ursodeoxycholic acid (norUDCA) is a side-chain shortened derivate of ursodeoxycholic acid (UDCA). Since norUDCA is only ineffectively conjugated with glycine or taurine, it has specific physicochemical and therapeutic properties distinct from UDCA. Nonamidated norUDCA undergoes cholehepatic shunting enabling 'ductular targeting' and inducing a bicarbonate-rich hypercholeresis, with cholangioprotective effects. At the same time it has direct anti-inflammatory, antilipotoxic, anti fibrotic, and antiproliferative properties targeting various liver cell populations. norUDCA appears to be one of the most promising novel treatment approaches targeting the liver and the bile duct system at multifactorial and multicellular levels. This review article is a summary of a lecture given at the XXIII International Bile Acid Meeting (Falk Symposium 194) on 'Bile Acids as Signal Integrators and Metabolic Modulators' held in Freiburg, October 8-9, 2014, and summarizes the recent progress with norUDCA as a novel therapeutic approach in cholestatic and metabolic (liver) disorders.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Trauner
authors.forename: Emina
authors.initials: E
authors.lastname: Halilbasic
authors.forename: Thierry
authors.initials: T
authors.lastname: Claudel
authors.forename: Daniel
authors.initials: D
authors.lastname: Steinacher
authors.forename: Claudia
authors.initials: C
authors.lastname: Fuchs
authors.forename: Tarek
authors.initials: T
authors.lastname: Moustafa
authors.forename: Marion
authors.initials: M
authors.lastname: Pollheimer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Krones
authors.forename: Christian
authors.initials: C
authors.lastname: Kienbacher
authors.forename: Stefan
authors.initials: S
authors.lastname: Traussnigg
authors.forename: Lili
authors.initials: L
authors.lastname: Kazemi-Shirazi
authors.forename: Petra
authors.initials: P
authors.lastname: Munda
authors.forename: Harald
authors.initials: H
authors.lastname: Hofer
authors.forename: Peter
authors.initials: P
authors.lastname: Fickert
authors.forename: Gustav
authors.initials: G
authors.lastname: Paumgartner
mesh_terms: D000818:Animals; D001649:Bile Duct Diseases / Q000188:drug therapy*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008659:Metabolic Diseases / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects; D014580:Ursodeoxycholic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D014580:Ursodeoxycholic Acid; C081331:24-norursodeoxycholic acid